Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

Abstract:

INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier stages of the disease, some clinicians even expect a disease-modifying effect. AREAS COVERED:In this review, the author provides a brief overview of the epileptic comorbidity in AD, discusses the appropriate AEDs from a syndromic point of view, reviews the effectiveness and cognitive tolerability of the currently available drugs, and considers the influence of the comorbidities and the age of AD patients in the choice of an AED. EXPERT OPINION:Given the paucity of current empirical data, much remains to be done to provide good evidence of the efficacy and tolerability of AEDs in the area of AD-related seizures and epilepsy. To our knowledge, lamotrigine and levetiracetam are currently the two best therapeutic options as low-dose monotherapies.

authors

Cretin B

doi

10.1080/14656566.2018.1496237

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

1201-1209

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

19

pub_type

杂志文章,评审
  • Meta-analysis of the efficacy of the fentanyl iontophoretic transdermal system versus intravenous patient-controlled analgesia in postoperative pain management.

    abstract:OBJECTIVE:This meta-analysis was conducted to analyze and compare the efficacy outcomes associated with the fentanyl iontophoretic transdermal system (ITS) and morphine intravenous (IV) patient-controlled analgesia (PCA) in the management of postoperative pain. RESEARCH DESIGN AND METHODS:This meta-analysis assessed t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析

    doi:10.1517/14656566.2015.1054279

    authors: Sinatra RS,Viscusi ER,Ding L,Danesi H,Jones JB,Grond S

    更新日期:2015-01-01 00:00:00

  • Novel therapy for childhood acute lymphoblastic leukemia.

    abstract:INTRODUCTION:During recent decades, the prognosis of childhood acute lymphoblastic leukemia (ALL) has improved dramatically, nowadays, reaching a cure rate of almost 90%. These results are due to a better management and combination of old therapies, refined risk-group stratification and emergence of minimal residual di...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340938

    authors: Santiago R,Vairy S,Sinnett D,Krajinovic M,Bittencourt H

    更新日期:2017-08-01 00:00:00

  • Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

    abstract:INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1114098

    authors: Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

    更新日期:2015-01-01 00:00:00

  • The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.

    abstract::A randomized Phase III trial tested the efficacy of pemetrexed as maintenance treatment in patients with advanced non-small-cell lung cancer (NSCLC) who were without progression after completing four cycles of first-line platinum-based chemotherapy. The primary endpoint of the trial was progression-free survival (PFS)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560903485672

    authors: Gridelli C,Di Maio M

    更新日期:2010-02-01 00:00:00

  • A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.

    abstract::Following Huggins' original observation of the dependence of the prostate on androgens, testosterone suppression by either orchiectomy or oestrogen compounds (e.g., diethylstilbesterol [DES]) became the standard palliative treatment for advanced prostate cancer. Early studies showed testosterone suppression improved s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.447

    authors: Perez-Marrero R,Tyler RC

    更新日期:2004-02-01 00:00:00

  • Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.

    abstract:IMPORTANCE OF THE FIELD:The emergence of fixed-combination drugs for the treatment of glaucoma has, to some extent, changed the medical management of glaucoma. The potential benefits of these drugs include a reduction in the total number of drops and preservatives instilled per day and improved patient comfort factors,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003667540

    authors: Razeghinejad MR,Sawchyn AK,Katz LJ

    更新日期:2010-04-01 00:00:00

  • Needed, new paradigms in antibiotic development.

    abstract::While antibiotic resistance has grabbed the headlines and the attention of the pharmaceutical industry, the lack of susceptibility of biofilms formed both on animate and inanimate surfaces deserve greater attention from the industry, medical practitioners and regulators. The current literature tells us that the inhere...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656561003724747

    authors: Ceri H,Olson ME,Turner RJ

    更新日期:2010-06-01 00:00:00

  • The treatment of Tourette's syndrome: current opinions.

    abstract::Correct education of the patient is one of the most important aspects in the treatment of Tourette's syndrome. Pharmacotherapy is often unsatisfactory and therefore should be limited to those patients who are significantly impaired. Therapy must be individualised and the most troublesome symptom should be targeted fir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.7.899

    authors: Müller-Vahl KR

    更新日期:2002-07-01 00:00:00

  • Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:Bronchodilators represent the mainstay of symptomatic treatment for chronic obstructive pulmonary disease (COPD). The principal bronchodilator agents are β(2)-agonists, anticholinergics and methylxanthines, used singly or in combination. Indacaterol is a novel long-acting β(2)-agonist for maintenance bronc...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2012.674513

    authors: Steiropoulos P,Papanas N,Nena E,Bouros D

    更新日期:2012-05-01 00:00:00

  • Pharmacological management of human respiratory syncytial virus infection.

    abstract:INTRODUCTION:Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. AREAS COVERE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1806821

    authors: Kalergis AM,Soto JA,Gálvez NMS,Andrade CA,Fernandez A,Bohmwald K,Bueno SM

    更新日期:2020-12-01 00:00:00

  • Current therapeutical strategies for allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option. AREAS COVERED:This review focuses...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1543401

    authors: Klimek L,Sperl A,Becker S,Mösges R,Tomazic PV

    更新日期:2019-01-01 00:00:00

  • Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database.

    abstract::Multiple approaches to enhancing antidepressant treatment response in bipolar depression are available and should, in many instances, be explored despite a lack of definitive controlled trial literature supporting their efficacy. Given that the morbidity of depression is three times greater than mania in bipolar illne...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.4.531

    authors: Post RM

    更新日期:2005-04-01 00:00:00

  • Vortioxetine: a New Treatment for Major Depressive Disorder.

    abstract:INTRODUCTION:Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1133588

    authors: Connolly KR,Thase ME

    更新日期:2016-01-01 00:00:00

  • Metabolic syndrome management.

    abstract::Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2059

    authors: Stone NJ,Schmeltz LR

    更新日期:2007-09-01 00:00:00

  • Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

    abstract:BACKGROUND:Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. OBJECTIVE:In this articl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2363

    authors: Barragan P,Podzamczer D

    更新日期:2008-09-01 00:00:00

  • Sibutramine: current status as an anti-obesity drug and its future perspectives.

    abstract:BACKGROUND:Obesity has become a global epidemic with recent estimates of > 400 million obese adults. Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2161

    authors: Sharma B,Henderson DC

    更新日期:2008-08-01 00:00:00

  • VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.

    abstract::Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for patients who after myocardial infarction (MI) present with either heart failure (HF) or left ventricular systolic dysfunction, or both. An alternative could be a more complete inhibition of the renin-angiotensin system through the bl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.6.3.507

    authors: Maggioni AP,Fabbri G

    更新日期:2005-03-01 00:00:00

  • The therapeutic management of differentiated thyroid cancer.

    abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.15.2627

    authors: Sipos JA,Mazzaferri EL

    更新日期:2008-10-01 00:00:00

  • 72nd Meeting of the American Heart Association. November 1999, Atlanta, Georgia, USA.

    abstract::The American Heart Association annual meeting must be one of the largest scientific gatherings, attracting over 30,000 delegates. The meeting at the end of last year was held in Atlanta, USA, the 2000 meeting will be in New Orleans, USA. The following highlights represent my own interests. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.1.3.581

    authors: Lunnon MW

    更新日期:2000-03-01 00:00:00

  • Non-insulin pharmacological therapies for treating type 1 diabetes.

    abstract:INTRODUCTION:Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of int...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1483339

    authors: Frandsen CS,Dejgaard TF,Madsbad S,Holst JJ

    更新日期:2018-06-01 00:00:00

  • High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.

    abstract:BACKGROUND:There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent lesion formation, decrease the rate and severity of relapses and delay the resulting disability by reducing levels of inflammation. OBJECTIVE:The aim of this review was to assess the treatment o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560802677882

    authors: Hartung HP

    更新日期:2009-02-01 00:00:00

  • Summarizing the FIELD study: lessons from a 'negative' trial.

    abstract:INTRODUCTION:Disturbances in lipid metabolism represent an integral component of dysglycemic states and may increase the risk of diabetic complications. Although from a pathophysiological viewpoint fibrates could represent the ideal drug for patients with diabetic dyslipidemia the evidence that support their use in the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.850075

    authors: Tsimihodimos V,Mikhailidis DP,Elisaf M

    更新日期:2013-12-01 00:00:00

  • Amyloidosis and POEMS syndrome.

    abstract:IMPORTANCE OF THE FIELD:Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. AREAS COVERED IN THI...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003769874

    authors: Chee CE,Dispenzieri A,Gertz MA

    更新日期:2010-06-01 00:00:00

  • Pharmacological treatment for insomnia in patients with major depressive disorder.

    abstract:INTRODUCTION:Insomnia in Major Depressive Disorder (MDD) is highly prevalent and associated with increased suffering and functional impairment. Effective, evidence-based treatments for insomnia in MDD are an unmet need in clinical practice. AREAS COVERED:Herein, the authors provide a review of the clinical correlates,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1614562

    authors: Brietzke E,Vazquez GH,Kang MJY,Soares CN

    更新日期:2019-08-01 00:00:00

  • Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.

    abstract:INTRODUCTION:Advances in acute lymphocytic leukemia (ALL) therapy has led to long-term survival rates in children. However, only 30%-40% of adults achieve long-term disease-free survival. After relapse, the outcome of salvage chemotherapy is very disappointing with less than 10% of long survival. Novel agents are there...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1250884

    authors: Thomas X,Le Jeune C

    更新日期:2016-12-01 00:00:00

  • Current and future treatments of alopecia areata and trichotillomania in children.

    abstract:INTRODUCTION:Treatment options for hair disorders are generally very limited. These options are even more limited in children due to the lack of trials and clinical research. Moreover, physicians are sometimes scared to treat children with drugs without safety data, especially because most hair disorders are benign. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217990

    authors: Iorizzo M,Oranje AP

    更新日期:2016-09-01 00:00:00

  • Pharmacological management of paracoccidioidomycosis.

    abstract::A systemic and endemic emerging mycosis in Latin America, paracoccidioidomycosis, is characterised by its chronicity and by the severity of the disseminated form in healthy individuals, as well as in immunocompromised individuals co-infected with HIV, resulting, in the latter, in a mortality rate in the range of 30 - ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.3.385

    authors: Yasuda MA

    更新日期:2005-03-01 00:00:00

  • Cost-effectiveness of pharmacotherapy for autoimmune hepatitis.

    abstract::In > 80% of patients with autoimmune hepatitis, steroid therapy alone or in combination with azathioprine results in disease remission. Treatment response results in reversal of fibrosis and excellent long-term survival in many patients, whereas untreated patients may expect a 10-year survival of < 30%. The use of aza...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.2.145

    authors: Heneghan MA,Al-Chalabi T,McFarlane IG

    更新日期:2006-02-01 00:00:00

  • Empagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.966078

    authors: Jahagirdar V,Barnett AH

    更新日期:2014-11-01 00:00:00

  • Emerging paradigms in targeted treatments for Asian patients with NSCLC.

    abstract:INTRODUCTION:EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapidly developed in Asia. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1040391

    authors: Ke EE,Zhou Q,Wu YL

    更新日期:2015-06-01 00:00:00